Highest-materiality recent filing
Faeth Therapeutics Q2 2026 net loss $16.0M; cash $186.4M; Phase 2 PIK-201 data expected year-end
Net loss of $16.0M ($2.84 per share) for Q2 2026, compared to $4.9M ($3.91 per share) in Q2 2025.
Faeth Therapeutics enters $150M ATM equity facility; Series B preferred converts to common
Entered Sales Agreement with TD Securities for at-the-market offering of common stock up to $150M.
Faeth Therapeutics (fka Sensei) appoints new CEO, CFO; PIKTOR Phase 2 data expected H2 2026
Name changed to Faeth Therapeutics; ticker to FTH effective June 16, 2026; Austin HQ.
Sensei Biotherapeutics stockholders approve 24x increase in authorized shares to 300M
Authorized common shares increased from 12.5M to 300M via charter amendment effective June 10.
Annual meeting on June 10, 2026 to vote on conversion of Series B Preferred Stock into common stock.
Sensei Biotherapeutics Q1 net loss $170.2M; cash $202.8M; PIKTOR trial advances
Net loss of $170.2M ($131.45 per share) vs $6.9M loss a year ago, driven by $133.0M acquired IPR&D charge from Faeth acquisition.
Three Sensei directors to resign, new CEO & CFO conditional on stockholder approval
Christopher Gerry, Thomas Ricks, Kristian Humer resigning conditionally effective after June 10, 2026 annual meeting, contingent on stockholder approval of Conversion and Charter Amendment Proposals.
Sensei Biotherapeutics files audited Faeth financials; net loss $16M in 2025, going-concern doubt
Faeth net loss $16.0M in 2025 ($18.3M in 2024); accumulated deficit $77.7M at Dec 31, 2025.
Sensei Biotherapeutics FY2025 net loss $21.1M; advances PIKTOR with $200M private placement
Net loss of $21.1M, or $(16.72) per share, compared to $30.2M loss in prior year.
Sensei Biotherapeutics closes merger with Faeth and $200M PIPE; existing holders diluted to ~4.9%
Issued ~10,602 Series B Preferred shares (each convertible into 1,000 common) to acquire Faeth; pre-PIPE: Faeth holders ~89.3%, Sensei ~10.7%.
Sensei discontinues solnerstotug, starts strategic review; workforce cut 65%
Discontinued solnerstotug development; Board considering sale, merger, or wind-down.
Sensei Biotherapeutics discontinues solnerstotug, initiates strategic review for sale or wind-down
Board discontinues development of solnerstotug after review of pipeline and market conditions.
6-month PFS of 50% in 15 mg/kg dose cohort in PD-(L)1 resistant patients vs historical ~10-20% for docetaxel.
Sensei Biotherapeutics Q2 net loss $4.9M; cash runway into Q2 2026; Phase 1/2 data year-end
Cash, cash equivalents and marketable securities $28.6M at June 30, 2025 (down from $41.3M at Dec 31, 2024).
Sensei Biotherapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq letter on July 2, 2025 confirming compliance with Rule 5550(a)(2).
Sensei Biotherapeutics announces 1-for-20 reverse stock split effective June 16
Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on June 16, 2025.
Net loss of $6.9 million for Q1 2025, down from $8.0 million in Q1 2024.
Preliminary Phase 1/2 dose expansion data: 14% ORR (3x historical PD-(L)1 rechallenge rates) and 62% DCR in PD-(L)1 resistant hot tumors; one complete response in Merkel cell carcinoma.
Sensei reports solnerstotug 14% ORR in PD-(L)1 resistant tumors; Phase 2 planned Q1 2026
14% ORR (3/21 evaluable) and 62% DCR in PD-(L)1 resistant 'hot' tumors; nearly 3x historical rechallenge response.
Sensei Biotherapeutics gets bid-price extension to July 7, 2025; transfers to Nasdaq Capital Market
Nasdaq approved transfer to Capital Market; trading under SNSE starts Jan 8, 2025.
Sensei Biotherapeutics cuts workforce 46%, extends cash runway into Q2 2026; Q3 net loss $7.3M
Net loss $7.3M for Q3 2024 vs $7.1M year ago; cash & securities $47.0M as of Sept 30.
Sensei Biotherapeutics receives Nasdaq bid-price deficiency notice; 180 days to cure
Nasdaq notified Sensei on July 10, 2024 that common stock closed below $1.00 for 30 consecutive business days.
Confirmed partial response (59% decrease) in an MSS endometrial cancer patient on SNS-101 plus cemiplimab; remains on study at 30+ weeks.
Sensei Biotherapeutics Q1 net loss narrows to $8M; SNS-101 Phase 1 dose escalation complete, no DLTs
Net loss of $8.0M for Q1 2024 vs $10.2M in Q1 2023; R&D spend $4.9M, G&A $3.8M.
Sensei Biotherapeutics CFO Erin Colgan resigns effective April 10, 2024
Erin Colgan resigns as CFO and all positions, effective April 10, 2024.
Sensei Biotherapeutics FY 2023 net loss $34.1M; cash into Q4 2025; SNS-101 data due Q2 2024
Net loss $34.1M in FY2023 vs $48.6M in FY2022; R&D expense fell to $18.3M from $30.4M.
Sensei Biotherapeutics board unanimously rejects Newtyn's $1.00/share takeover bid
Received unsolicited proposal from Newtyn Management to acquire all shares at $1.00/share in cash.
Sensei Biotherapeutics reports favorable Phase 1/2 data for SNS-101 at SITC 2023
SNS-101 dose escalation (13 patients): well-tolerated, no DLTs, no CRS; only one related AE (Grade 2 dermatitis).
Sensei Biotherapeutics receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Sensei on Oct 17, 2023 that stock bid price <$1 for 30 consecutive days, violating Listing Rule 5450(a)(1).
Sensei Biotherapeutics Q2 2023 net loss $9.4M; SNS-101 Phase 1/2 enrolling 6 patients
Cash, cash equivalents and marketable securities $78.8M at June 30, 2023, down from $107.1M at Dec 31, 2022; cash runway into H2 2025.
On September 11, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately.
The Board of Directors (the “Board”) of the Company appointed Anand Parikh as President and Chief Executive Officer of the Company, effective as of June 13, 2026
Effective as of June 13, 2026, Brian Stephenson was appointed as the Company’s Chief Financial Officer and principal financial officer.
effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.
effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.
effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.
Effective as of June 13, 2026, Josiah Craver was ratified as the Company’s Senior Vice President of Finance and appointed as principal accounting officer.
On October 25, 2024, Deneen Vojta, MD notified the Chair of the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) of her decision to resign from the Board, effective December 31, 2024.
In connection with such appointment, David Gaiero, who was serving as the Company’s principal financial officer and principal accounting officer on an interim basis, ceased serving in such capacities as of the Effective Date.
On September 17, 2024, the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed Josiah Craver as the Company’s principal financial officer and principal accounting officer, effective immediately
On June 26, 2024, Jessie English, PhD notified the Chair of the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) of her decision to resign from the Board, effective July 1, 2024.
On April 11, 2024, Sensei Biotherapeutics, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Erin Colgan, the Company’s former Chief Financial Officer.
Max materiality 1.00 · Median 0.60 · Most common event other_material